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Fisher's method
Fisher's method [8] is one of the most widely used methods for combining independent p-values. Considering a set of m independent significance tests, the resulting p-values P1, P2, . . . , Pm are independent and uniformly distributed on the interval [0, 1] under the null hypothesis. Denoting Xi = −2 ln Pi (i ∈ {1, 2, . . . , m}) as new random variables, the cumulative distribution function of Xi can be calculated as follows:
Fi(x) = P r(Xi ≤ x) = P r(−2 ln Pi ≤ x) = P r(Pi ≥ e
The above function is the cumulative distribution function of a chi-squared distribution with two degrees of freedom (χ 2 2 ). Since the sum of chi-squared random variables is also a chi-squared random variable, −2 m i=1 ln(Pi) follows a chi-squared distribution with 2m degrees of freedom (χ 2 2m ). In summary, the log product of m independent p-values follows a chi-squared distribution with 2m degrees of freedom:
We note that if one of the individual p-values approaches zero, which is often the case for empirical p-values, then the combined p-value approaches zero as well, regardless of other individual p-values. For example, if P1 → 0, then X → ∞ and therefore, P r(X) → 0 regardless of P2, P3, . . . , Pm. Therefore, we see that Fisher's method is sensitive to outliers.
add-CLT
The additive method [9, 11, 7] uses the sum of the p-values as the test statistic, instead of the log product. Let us denote the p-values resulting from the m independent significance tests as P1, P2, . . . , Pm. These p-values are independent and uniformly distributed between zero and one under the null (i.e. all p-values between zero and one are equally probable when the null hypothesis is true). Denote the sum of these p-values, X = m i=1 Pi (X ∈ [0, m]), as the new random variable. X is known to follow the Irwin-Hall distribution [9, 11] with the following probability density function (pdf):
Unlike Fisher's method, the additive method is not sensitive to small individual p-values. However, we note that the additive method faces a different practical problem. For large values of m, Equation (2) involves some intensive computation due to a sum of combinatorial and division by a factorial, the result of which can lead to an "arithmetic underflow". Here we describe an enhancement to the additive method that makes it more reliable for larger values of m. First, we change the random variable from the sum of the p-values to the average of the p-values. Second, when m is large, we replace the additive method with the Central Limit Theorem (CLT). The reason for the modification is that the additive method is accurate for small values of m, while the Central Limit Theorem is more accurate for large values of m. We select m = 20 as a conservative cut-off. In other words, we will use the additive method when m < 20, and the Central Limit Theorem when m ≥ 20.
To show the validity of using the Central Limit Theorem for large m, we define a new random variable Y = m i=1 P i m (Y ∈ [0, 1]), which is the average of p-values. Since Y = X m , we can derive the probability density function (pdf) of Y using a linear transformation of X as follows:
The corresponding cumulative distribution function (cdf) can be calculated as:
The variable Y is the mean of m independent and identically distributed (i.i.d.) random variables (the p-values from each individual experiment), that follow a uniform distribution with a mean of 1 2 and a variance of 1 12 . From the Central Limit Theorem [12] , the average of such m i.i.d. variables follows a normal distribution with mean µ = 1 2 and variance σ 2 = 1 12m , i.e. Y ∼ N ( 1 2 , 1 12m ) for sufficiently large values of m.
Standardized mean difference
Consider a study composed of two independent groups, and suppose we wish to compare their means for a given gene. LetX1 andX2 represent the sample means for that gene in the two groups, n1 and n2 the number of samples in each group, and S pooled the pooled standard deviation of the two groups. The pooled standard deviation and the standardized mean difference (SMD) can be estimated as:
The estimation of the standardized mean difference described in Equation (6) is often called Cohen's d [4, 3] . The variance of Cohen's d is given as follows:
In the above equation, the first term reflects uncertainty in the estimate of the mean difference, and the second term reflects uncertainty in the estimate of S pooled . The standard error of d is the square root of V d . We note that Cohen's d, which is based on sample averages, tends to overestimate the population effect size for small samples. Let n be the degrees of freedom used to estimate S pooled , i.e. n = n1 + n2 − 2. The corrected effect size, or Hedges' g [10] , can be computed as follows:
where Γ is the gamma function. In this work, we use Hedge' g as the standardized mean difference (SMD) between disease and control groups for each gene/miRNA.
Results
Experimental data
We use 182 human signaling pathways extracted as graph objects from KEGG. We use expression data related to Alzheimer's disease (10 datasets), influenza (9 datasets), and acute myeloid leukemia (8 datasets) , available at https://www.ncbi.nlm.nih.gov/geo/. The total number of samples is 1,737. Table S1 shows the summary information for each dataset, including number of samples, platforms, tissues, etc. For each dataset, we process the raw data using the threestep function from the package affyPLM [2] . The parameters used for the threestep function are: robust multi-array analysis (RMA) background adjustment, quantile normalization, and median polish summarization. If the raw data are not available, we use the data that are already processed and normalized by the data providers.
For subtyping purpose, we also download RNA-Seq data for AML patients. The processed data are available at the Broad Institute's website http://gdac.broadinstitute.org/. The total number of patients for this cohort is 167 and the number of genes is 20,100. We also download the vital status and follow-up information from the same website. The survival information is used to plot the Kaplan-Meier survival curves and to calculate the Cox p-values. 
Pathway analysis
Here we use 10 different integrative approaches to identify the impacted pathways of the 27 datasets: the proposed NBIA, 6 GSA-, GSEA-, and IA-related approaches, and 3 MetaPath methods. For implementation of the NBIA, we used functions from the following R packages: BLMA [16, 15, 14] , ROntoTools [25] , limma [20] , and metafor [24] . NBIA will be available in the package BLMA's next release. The top pathways of NBIA are shown in Tables 1, 2, and 3 in the main text while those of the other 9 methods are shown in Tables S2, S3, and S4 in this supplemental document. Table S2 : The 20 top ranked pathways and FDR-corrected p-values obtained by combining Alzheimer's data using 9 different approaches: 3 MetaPath methods and 6 GSA-, GSEA-, and IA-related approaches. The horizontal line shows the 5% cutoff. The pathways Alzheimer's disease, Huntington's disease, and Parkinson's disease are highlighted in green. MetaPath P, Meta-Path G, and MetaPath I fail to identify the target pathway Alzheimer's disease as significant, and rank it at the positions 74 th , 81 st , and 58 th , respectively. The other six methods, GSA+Fisher, GSA+addCLT, GSEA+Fisher, GSEA+addCLT, IA+Fisher, and IA+addCLT, rank the target pathway at the positions 32 nd , 10 th , 27 th , 13 nd , 55 th , and 96 th , respectively. Table S3 : The 20 top ranked pathways and FDR-corrected p-values obtained by combining influenza data using 9 different approaches: 3 MetaPath methods and 6 GSA-, GSEA-, and IA-related approaches. The horizontal line shows the 5% cutoff. The target pathway Influenza A is highlighted in green. GSA+Fisher, GSEA+addCLT, IA+Fisher, and IA+addCLT identify the target pathway as significant and rank it at the positions 13 th , 37 rd , 1 st , and 2 nd , respectively. 
Subtyping AML data
Using the pathway signatures of the meta-analysis methods, we perform subtyping on 167 AML samples downloaded from the Broad Institute's website http://gdac.broadinstitute.org/. The four methods, MetaPath I, MetaPath G, MetaPath P and GSA+addCLT, yield no significant pathway and thus have no pathway signature. We use the pathway signatures of the remaining six methods to subtype AML patients. We also subtype the AML patients using all genes. The Cox p-values obtained for each analysis are shown in Table 4 in the main text. The Kaplan-Meier survival analysis of the discovered subtypes for all genes and NBIA is shown in Figure 3 in the main text. The Kaplan-Meier survival analysis for the remaining methods is shown in Figure S1 . The heatmaps in Figure S2 visualize different subtypes of AML patients derived from either on all genes and NBIA signature. The left panels in Figure S2 show the the heatmaps of subtypes discovered using all genes while the right panels show those using NBIA signature. In these panels, the columns represent the patients and different colors on the top stripe shows different subtypes. To provide the genes that are most meaningful in defining the subtypes, we also performed an analysis of variance (ANOVA) and selected genes that are most significant. The rows in each panel shows the 30 top genes with the most significant p-values. 3 Discussions and simulation studies
On the impact of using both p-addCLT and p-effect size
The intuition of using both p-addCLT and p-effect-size is to combine the two types of p-values in order to reduce potential false positives. We want to make sure that the identified differentially expressed genes are not only significant from the classical hypothesis testing perspective, but also have estimated effect sizes (expression change) that are outside the range of standard errors. By default, genes with both of the p-addCLT and p-effect-size smaller than the threshold of F DR = 1% are considered as differentially expressed. We note that to have a p-value of 1%, the absolute z-score must be at least 2 (z = µ σ where µ is the estimated effect size and σ is the standard error). Therefore, with a cutoff of 1% we choose genes that are not only significant using the empirical Bayesian test, but also have the absolute effect size at least twice the standard error. From another perspective, the rationale of using both p-addCLT and p-effect-size is similar to the differential expression analysis using a volcano plot, which combines a measure of statistical significance from a statistical test with the magnitude of the change. The difference here is that instead of focusing on the magnitude, we focus on confirming that the magnitude of the change is well beyond the margin of error. This also allows us to avoid introducing another threshold for effect sizes.
The contribution of each type of p-values depends on the data. For example, p-addCLT contributes more in Alzheimer's data while p-effect-size contributes more in Influenza and AML data. Figure S3 shows the scatter plots of p-addCLT versus p-effect-size. A gene is considered DE if both p-addCLT and p-effect-size are significant, i.e., the gene belongs to the upper right quarter in the plot. In case of Alzheimer's data ( Figure S3A ), if we removed p-addCLT from the analysis, then we would have obtained a large number of DE genes (genes in upper and lower right quarters), among which many are potentially false positives. Therefore, we would say that p-addCLT contributes more to the analysis in Alzheimer' data. In the case of AML ( Figure S3B ), most of DE genes are determined by p-effect-size. Removing p-addCLT from this analysis will make a small difference since there are only 5 genes that belong to the lower right panel. Therefore, we would say p-effect-size contributes more in Influenza and AML data analysis ( Figure S3B 
On the contribution of the hypergeometric model and the perturbation factor model
We expect that each model captures a different type of evidence for differential expression. Therefore, the contribution of each model is expected to be complementary to one another. The hypergeometric model, also known as overrepresentation analysis [6, 21] , estimates the p-value as the probability of obtaining at least the observed number of differentially expressed genes (DE) just by chance. Therefore, it captures the significance of the given pathway from the perspective of the set of genes contained in it. In contrast, the perturbation factor (PF) model aims at capturing the meaningful changes on a given gene topology. This captures the perturbation while taking into consideration the position and role of every gene, and the direction and type of every signal on the pathway. For instance, the insulin processing pathway has the insulin receptor (INSR) as the only entry point in this pathway. Indeed, if the insulin receptor is somewhat disabled, the cell will not be able to process insulin in a normal way and this cell function will be severely disrupted. However, the enrichment analysis will not yield a significant p-value if INSR is the only differentially expressed gene on this pathway. In contrast, the impact analysis will be able to report this pathway as significantly impacted because it takes into consideration the topology of the pathway and propagates the measured changed of the INSR throughout the rest of the pathway. Thus, the mathematical model employed by the impact analysis will be able to recognize the fact that disabling the entry point in the pathway will shut off the entire pathway [5] . The p-value of the PF model is the probability of obtaining a PF statistic at least as extreme as the one observed under the null hypothesis. A recent very thorough review and benchmarking has shown that the topology based pathway analysis methods are indeed better than the enrichment based methods [17] .
We expect the hypergeometric model to play a crucial role in the following scenarios: (i) the gene topology is not available or inaccurate, or (ii) the DE genes are disconnected. In fact, in the those cases, the hypergeometric model is the only meaningful model among the two. However, while useful for the purpose of gene set analysis, this model completely ignores the information about gene topology. In contrast, the PF model aims at fully exploiting all the knowledge about how genes interact as described in the pathway. Figure S4 illustrates an example analysis of a five-gene pathway. In this example, we monitor a total of 30 genes, among which five are found to be differentially expressed (DE). Two of the DE genes belong to the pathway. Regardless of the position of the DE genes on the pathway, the hypergeometric test provides a p-value of p de = 0.183, which is not significant. Now we present two cases in which the positions of the DE genes greatly influence the perturbation factor and its p-value (ppert). In the first case, the DE genes are leaf nodes and cannot perturb the activity of any other genes (the left graph in Figure S4 ). Gene A does not have any upstream gene nor differentially expressed and therefore P F (A) = 0. Similarly, P F (B) = P F (D) = 0. For gene C and D, the perturbation factor equals to effect size of the gene, i.e., P F (C) = P F (D) = 2. The total perturbation factor (PF) of the pathway is 4. Comparing this total PF against the null distribution constructed for the pathway, we obtain ppert = 0.272. Combining p de with ppert using Fisher's method, we obtain a p-value of p comb = 0.199, which is not significant.
In the second case, the DE genes have the ability to influence the activity of other genes (the right graph in Figure S4 ). Again, we start the calculation from gene A. This gene does not have any upstream gene and therefore its perturbation factor is equal to its effect size P F (A) = 2. For gene B, P F (B) = 2 + P F (A) = 4. For each of the gene C, D, and E, the perturbation factor is one third of gene B. Therefore, P F (C) = P F (D) = P F (E) = 4 3 . The total perturbation factor for the second case is 10. Comparing the total PF against the null, we have ppert = 0.025. Combining p de with ppert using Fisher's method, we have p comb = 0.029. In summary, the positions of the DE genes play an important role in the PF model. The two obtained p-values greatly differ even when we have the exact same number of DE genes with the same effect size. Figure S4: Impact Analysis (IA) using perturbation factor model. The figure shows a five-gene pathway with two differentially expressed (DE) genes in two different situations. In both cases, we have the same number of differentially expressed (DE) genes (marked in green). An ORA would find the two situations equally not significant (p de = 0.183 for a set of 30 monitored genes, out of which five are found to be DE). In the first situation (graph in the left), the two DE genes (C and D) are leaf nodes and cannot perturb the activity of any other pathway. In the second situation (graph in the right), the two DE genes (A and B) have the ability to influence the remaining genes in the pathway. This leads to a higher perturbation factor and a more significant ppert.
On batch effects and data heterogeneity
In the NBIA framework, we estimate the effect sizes of in each dataset/study separately and then combine them using a random-effects model. We use the standardized mean difference as the metric to measure effect size, which standardizes the results of each study to a uniform scale before they can be combined. This metric is designed to be robust against the scale of the original data [10, 4, 3] . In addition, the random-effects model includes batch effects and data heterogeneity in the design: yi = µ + τi + i. In this formula, µ is the central tendency and τi is the term by which the effect size in the i th study different from the central tendency. The τi variables represent batch effects and data heterogeneity among datasets [13, 23] . In other words, this model includes batch effects as a covariate in the designated formula thus explicitly removing the batch effects. That was the main reason we favored the random-effects model over the fixed-effects model when designing NBIA.
To demonstrate that the method is robust against batch effects and data heterogeneity, we simulated a scenario in which data samples were obtained from different data distributions that represent different batches. We first put together 197 control samples obtained from the eight AML datasets analyzed in our manuscript. The data distributions of the 197 samples are shown in Figure S5 . As shown in the figure, samples from different datasets have distinctively different expression distributions. These differences represent batch effects and data heterogeneity, including differences between population subgroups (e.g., different ethnicities, gender, race, or living conditions). Next, we randomly selected 20 samples from the sample pool and split them into two equal groups: disease and control. We repeated this process ten times to generate ten datasets. Since samples of both "disease" and "control" groups are randomly drawn from the same pool, a good statistical method should see no difference between these random groups.
In the next step, we altered the gene expression of nine specific genes in the FoxO signaling pathway for the samples assigned to the "disease" group. Figure S6 shows the FoxO signaling pathway that we focused on. The reason for choosing this KEGG pathway in this simulation is that it consists of a number of genes that do not appear in any other KEGG pathways, thus avoiding cross-talk effects between pathways [5] . The entries marked in red consist of genes that only appear on this pathway: (1) SET9 (gene symbol SETD7 with Entrez ID 80854), Figure S7 , in which SETD7 represses FOX06, and FOX06 activates seven remaining genes. We used the package simPATHy [18] to fit the expression of the ten simulated datasets to the subnetwork shown in Figure S7 and to simulate differential expression for disease samples. In each dataset, the gene SETD7 is down-regulated, leading to the up-regulation of the remaining genes in the subnetwork. The software did not alter expression values of any other genes. Now we use NBIA to perform a meta-analysis of the ten datasets including the tweaked genes on the FoxO signaling pathway. For each gene in each dataset, NBIA calculates: i) a p-value using limma, and ii) an effect size. Next, it combines the p-values across the ten datasets using addCLT to obtain a p-addCLT for each gene. The method also combines the effect sizes to obtain an overall effect size and a p-effect-size for each gene. Figure S8A shows the volcano plot of p-addCLT versus effect size. The horizontal axis represents effect size while the vertical axis represents minus log of FDR-corrected p-addCLT. The figure shows that the gene SETD7 is down-regulated with an approximate effect-size of −1.5 while the other eight genes of the subnetwork are up-regulated with effect (A) (B)
Volcano plot (p−addCLT versus effect size)
Effect size −log10 p−addCLT.fdrS5: The 5 top ranked pathways and FDR-corrected p-values obtained from the ten simulated datasets using ten metaanalysis approaches: NBIA, three MetaPath methods, and six GSA-, GSEA-, and IA-related approaches. The horizontal line shows the cutoff of F DR = 5%. The target pathway FoxO signaling pathway is highlighted in green. Only NBIA and GSA+Fisher identify the target pathway as significant and rank it on top. size of 1 or higher. Figure S8B shows the scatter plot of p-addCLT versus p-effect-size. The genes in the subnetwork have p-values of 10 −5 or smaller. The p-values of all other genes equal to 1 after FDR correction (both p-addCLT and p-effect-size). Using a default cutoff of F DR = 1% on both p-addCLT and p-effect-size, NBIA identified exactly the genes in the impacted subnetwork as significant. Table S5 shows the 5 top ranked pathways and FDR-corrected p-values at the pathway level analysis. NBIA correctly identifies FoxO signaling pathway as the only significantly pathway. We also analyzed the data using the other nine meta-analysis approaches: three MetaPath methods and six GSA-, GSEA-, and IA-related approaches. The three MetaPath methods identify no pathway as significant. GSA+Fisher is able to identify the target pathway as significant and ranks it on top. However, this method also identifies three other pathways as significant, which are clearly false positives. The reason is that the p-value for these pathways is zero in one of the datasets and Fisher's method always provides a combined p-value of zero when an individual p-value is zero. GSA+addCLT produces no false positives and also ranks the target pathway on top. However, it is not powerful enough to identify the target pathway as significant. The next method, GSEA+Fisher, produces four false positives. The remaining three methods identify no pathway as significant.
Assessing false positive rate via simulation
In order to assess the false positive rate of NBIA, we generated datasets under the null hypothesis and then calculated the number of pathways that are identified as significant using NBIA. Similar to the simulation described above, we created a pool of 197 control samples obtained from the eight AML datasets. To simulate a dataset under the null hypothesis, we randomly selected 20 samples from the pool and split them into two equal groups: disease and control. In the first scenario, we set the number of datasets (m) to 5. In this scenario, we generated five datasets and then analyzed the data using NBIA. Pathways with p-values smaller than the significance threshold (F DR = 5%) are considered false positives. The number of significant pathways divided by the total number of pathways is considered false positive rate (FPR). We repeated this process ten times and calculate the average FPR for m = 5. In the next scenarios, we increased m and repeated the process described above to compute the average FPR for different values of m.
The average false positive rates for varying values of m are shown in Figure S9A . Overall, NBIA has 0% FPR. As described in the Methods Section, the gene-level analysis produces two lists of p-values -p-addCLT and p-effect-size. These p-values are adjusted using False Discovery Rate (FDR). A gene is considered DE is both of its adjusted p-values are smaller than the threshold of F DR = 1%. These significant genes then serve as input of the Impact Analysis method. Again, the p-values obtained from the pathway-level analysis are adjusted using FDR. Pathways with p-values smaller than the threshold of F DR = 5% are considered as significant. The 0% false positive rate are mainly due to the rigorous procedure of selecting differentially expressed (DE) genes and the two levels of FDR correction.
To demonstrate the impact of FDR correction steps, we repeated the analysis with the following modifications to NBIA: (i) we removed the FDR adjustment at both gene and pathway levels, and (ii) we set the significance threshold to 5% for both gene-and pathway-level analysis. In this scenario, the FPR is close to the significance threshold of 5% regardless of the number of datasets to be combined ( Figure S9B ). 
